Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study

作者：Tom Loosli, Carolyn Bolton‐Moore, Lydia Buzaalirwa, Helen Byakwaga, İpek Çelikağ, Cleophas Chimbetete, Peter Vanes Ebasone, Jennifer Giandhari, Nuri Han, Jacqueline Huwa, Charles Kasozi, Adolphe Mafoua, Eugène Messou, Albert Minga, Guy Muula, Winnie Muyindike, Arcel Christ Massamba Ndala, Mamatha Sauermann, Aggrey Semeere, Lavanya Singh, Roger D. Kouyos, Richard Lessells, Matthias Egger · 发表于：Clinical Infectious Diseases · 年份：2025 · DOI：10.1093/cid/ciaf204 · 被引用次数：13 · 研究领域：HIV/AIDS drug development and treatment、HIV Research and Treatment、HIV/AIDS Research and Interventions

Dolutegravir resistance is an increasing concern. An analysis of the DTG RESIST study found that among 227 integrase sequences from 7 African countries (all non-B subtypes), 59 (26.0%) had at least 1 major drug resistance mutation (primarily G118R and E138A/K/T), with 49 (21.6%) predicted to have high-level resistance to dolutegravir.